Complete Response Letter NDA 505b1 205508 (Jul 28, 2025)

Summary

This document is a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) to an applicant for New Drug Application (NDA) 205508. The FDA has determined that the application cannot be approved in its present form due to several deficiencies related to facility inspections, manufacturing process controls (CMC data), and bioequivalence/bioavailability data reliability. The letter outlines specific reasons for non-approval and provides recommendations for addressing these issues, including requirements for resubmission and potential re-inspection of facilities.

Key points

• The facility must provide satisfactory responses to CGMP deficiencies identified during the inspection to the FDA office indicated on the FDA Form 483 prior to the complete response submission.
• The applicant must coordinate with the facility for timely resolution of deficiencies.
• The complete response submission must include the date(s) of the facility’s response(s) to the FDA Form 483 observations.
• Satisfactory outcomes of both the PAI (Pre-Approval Inspection) and CGMP surveillance inspections will be needed prior to approval of the application.
• The applicant must submit the entire CMC data package for the new bio-batch to be used in the new BE study and any additional data generated at the new manufacturing facility for all applicable sections of Module 3 (including 3.2.P.3 and 3.2.R) in the resubmission.
• The cover letter of the resubmission must prominently identify that it contains new CMC data.
• The applicant must provide further clarification in the cover letter and in Module 3 of the resubmission regarding whether a specific facility is being withdrawn or delisted as a commercial manufacturer, and if data from that facility will be retained.
• The applicant must resubmit or take other actions available under 21 CFR 314.110 within one year after the date of this letter.

Cited reasons

• Unsatisfactory CGMP Inspection Findings at Manufacturing Facility
• Inadequate CMC Data for New Bio-batch and Manufacturing Facility
• Reliability Concerns with Previous Bioequivalence Study Data
• Labeling Comments Reserved
• The FDA issued a Complete Response Letter primarily due to unsatisfactory CGMP inspection findings at a manufacturing facility, leading to concerns about the reliability of previously submitted bioequivalence data. Additionally, the application lacks sufficient CMC data for a new bio-batch and manufacturing facility. Comments on labeling are reserved until these core issues are resolved.

Recommended actions

• The facility must provide satisfactory responses to CGMP deficiencies identified during the inspection to the FDA office indicated on the FDA Form 483 prior to the complete response submission.
• The applicant must coordinate with the facility for timely resolution of deficiencies.
• The complete response submission must include the date(s) of the facility’s response(s) to the FDA Form 483 observations.
• Satisfactory outcomes of both the PAI (Pre-Approval Inspection) and CGMP surveillance inspections will be needed prior to approval of the application.
• The applicant must submit the entire CMC data package for the new bio-batch to be used in the new BE study and any additional data generated at the new manufacturing facility for all applicable sections of Module 3 (including 3.2.P.3 and 3.2.R) in the resubmission.
• The cover letter of the resubmission must prominently identify that it contains new CMC data.
• The applicant must provide further clarification in the cover letter and in Module 3 of the resubmission regarding whether a specific facility is being withdrawn or delisted as a commercial manufacturer, and if data from that facility will be retained.
• The applicant must resubmit or take other actions available under 21 CFR 314.110 within one year after the date of this letter.

Deficiency summary

The FDA issued a Complete Response Letter primarily due to unsatisfactory CGMP inspection findings at a manufacturing facility, leading to concerns about the reliability of previously submitted bioequivalence data. Additionally, the application lacks sufficient CMC data for a new bio-batch and manufacturing facility. Comments on labeling are reserved until these core issues are resolved.

Findings

Regulatory context

Submission stage

final decision

Regulatory pathway

NDA

Impact

Impact score

0.95

Estimated delay

545 days

Estimated rework cost

$0

Subsequent action

resubmission

Strategic insights

The primary themes of this Complete Response Letter are critical manufacturing quality system deficiencies (CGMP non-compliance) at a key facility, leading to a lack of confidence in the bioequivalence data and requiring new CMC data for a new manufacturing site. Labeling issues are secondary and contingent on resolving these core manufacturing and data integrity concerns.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 5%